FDA again re­jects Ab­b­Vie's con­tin­u­ous in­fu­sion ther­a­py for Parkin­son's

The FDA has re­ject­ed a new Parkin­son’s drug from Ab­b­Vie for a sec­ond time.

Reg­u­la­tors turned away AB­BV-951, a 24-hour in­fu­sion ther­a­py to treat ad­vanced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.